Antibody responses to inactivated and mRNA SARS-CoV-2 vaccines in familial Mediterranean fever patients treated with interleukin-1 inhibitors.
作者信息
Ugurlu Serdal, Akcin Ruveyda, Ayla Ali Yagiz, Kocazeybek Bekir, Oztas Mert, Can Gunay, Mustafayeva Leyla, Saltoglu Nese, Yilmaz Betul, Ozdogan Huri
机构信息
Division of Rheumatology, Department of Internal Medicine.
Department of Medical Microbiology.
出版信息
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI194-SI196. doi: 10.1093/rheumatology/keac123.
Abstract
摘要
相似文献
1
Antibody responses to inactivated and mRNA SARS-CoV-2 vaccines in familial Mediterranean fever patients treated with interleukin-1 inhibitors.
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI194-SI196. doi: 10.1093/rheumatology/keac123.
2
Clinical impact and disease evolution of SARS-CoV-2 infection in familial Mediterranean fever.
Pharmacol Res. 2022 Aug;182:106293. doi: 10.1016/j.phrs.2022.106293. Epub 2022 Jun 9.
3
Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19.
Lancet Microbe. 2021 Sep;2(9):e423. doi: 10.1016/S2666-5247(21)00177-4. Epub 2021 Jul 16.
4
Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine.
Rheumatol Int. 2022 Jun;42(6):973-987. doi: 10.1007/s00296-022-05119-y. Epub 2022 Apr 4.
5
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies.
Mult Scler Relat Disord. 2022 Feb;58:103486. doi: 10.1016/j.msard.2022.103486. Epub 2022 Jan 10.
6
COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study.
Rheumatol Int. 2021 Apr;41(4):715-719. doi: 10.1007/s00296-021-04812-8. Epub 2021 Feb 21.
7
Comparison of long-term antibody response to mRNA SARS-CoV-2 vaccine among peritoneal dialysis and hemodialysis patients.
Nephrol Dial Transplant. 2022 Feb 25;37(3):602-604. doi: 10.1093/ndt/gfab321.
8
Blunted humoral response after mRNA vaccine in patients with haematological malignancies.
Lancet Haematol. 2021 Aug;8(8):e540-e542. doi: 10.1016/S2352-3026(21)00197-6. Epub 2021 Jul 2.
9
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Mult Scler Relat Disord. 2022 Mar;59:103690. doi: 10.1016/j.msard.2022.103690. Epub 2022 Feb 13.
10
Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.
EBioMedicine. 2021 Sep;71:103567. doi: 10.1016/j.ebiom.2021.103567. Epub 2021 Aug 26.
引用本文的文献
1
Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors.
J Clin Med. 2023 Jul 18;12(14):4741. doi: 10.3390/jcm12144741.
2
Current Evidence on Vaccinations in Pediatric and Adult Patients with Systemic Autoinflammatory Diseases.
Vaccines (Basel). 2023 Jan 10;11(1):151. doi: 10.3390/vaccines11010151.
本文引用的文献
1
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.
Respirology. 2022 Apr;27(4):301-310. doi: 10.1111/resp.14191. Epub 2021 Nov 24.
2
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19.
Lancet Rheumatol. 2021 Dec;3(12):e829-e831. doi: 10.1016/S2665-9913(21)00321-0. Epub 2021 Oct 29.
3
COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics.
Rheumatol Adv Pract. 2021 Aug 23;5(2):rkab043. doi: 10.1093/rap/rkab043. eCollection 2021.
4
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3.
Arthritis Rheumatol. 2021 Oct;73(10):e60-e75. doi: 10.1002/art.41928. Epub 2021 Aug 4.
5
Incidence and course of COVID-19 hospitalizations among patients with familial Mediterranean fever.
Rheumatology (Oxford). 2021 Oct 9;60(SI):SI85-SI89. doi: 10.1093/rheumatology/keab577.
6
Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic.
Int J Rheum Dis. 2021 Jun;24(6):733-745. doi: 10.1111/1756-185X.14124. Epub 2021 May 4.
7
The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.
Int J Infect Dis. 2021 Apr;105:756-762. doi: 10.1016/j.ijid.2021.03.031. Epub 2021 Mar 15.
8
Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study.
Clin Vaccine Immunol. 2010 Dec;17(12):1952-7. doi: 10.1128/CVI.00175-10. Epub 2010 Oct 20.
Zotero 插件